[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oncology Institute of Southern Switzerland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":213},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,74,95,116,135,153,170,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053816","lucinae-registry-thoracic-cancers-during-pregnancy-100053816",false,"NCT07699861","LUCINAE Registry: Thoracic Cancers During Pregnancy","LUCINAE: LUng and Thoracic Cancers In pregNAncy rEgistry","LUCINAE","Inclusion Criteria:\n\n* 1\\. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:\n\n  1. Patients receiving a diagnosis of thoracic cancer during pregnancy\n  2. Patients who became pregnant while having active thoracic cancer\n  3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.\n* 2\\. Available information about pregnancy outcomes\n* 3\\. Age ≥ 18 years\n\nExclusion Criteria:\n\n* 1\\. Patient missing data about thoracic cancer stage and diagnosis\n* 2\\. For retrospective patients, documented refusal to the use of clinical data for research purposes","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.\n\nBecause thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.\n\nThe results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.",[25,26,27],"Lung Cancer","Thoracic Cancer","Cancer During Pregnancy",[29,30],"thoracic cancers during pregnancy","Lung cancer during pregnancy","RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2035-12",{"name":41,"class":42},"Oncology Institute of Southern Switzerland","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100611016","effect-of-a-music-intervention-in-reducing-distress-and-pain-in-patients-with-lung-cancer-undergoing-mini-invasive-surgery-100611016","NCT07235098","Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery","Effect of a Music Intervention in Reducing Distress and Pain in Patients With Suspected or Diagnosed Lung Cancer Undergoing Mini-Invasive Surgery","Inclusion Criteria:\n\n* Suspected or confirmed diagnosis of lung cancer\n* Age ≥ 18 years\n* Indication for lung resection through a minimally invasive surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Endocrinological disorders involving cortisol axis\n* Chronic steroid intake \\> 10 mg\u002Fday\n* Concomitant treatment with drugs against symptomatic anxiety and\u002For depression\n* Partial or complete hearing loss\n* Inability to follow the schedule of investigation\n* Patient unwilling to refrain from actively listening to other music (e.g., via other personal devices\u002Fheadphones) outside of the prescribed musical intervention defined by the study protocol during the hospitalization.",{"count":52,"type":21},74,"INTERVENTIONAL",[55],"NA","This study aims at evaluating whether music therapy intervention is effective in decreasing psychological (distress) and physical symptoms (pain) in patients with suspected or diagnosed lung cancer undergoing minimally invasive lung surgery.",[58],"Lung Cancer (Suspected or Confirmed)",[60,61,62,63],"lung cancer","pain","anxiety","music","NOT_YET_RECRUITING","2025-11-14",{"date":67,"type":35},"2025-11-19",{"date":69,"type":21},"2025-12-15",{"date":71,"type":21},"2027-12-31",{"name":41,"class":42},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":73},"100514928","the-immune-landscape-of-epithelial-ovarian-cancer-100514928","NCT05984875","The Immune Landscape of Epithelial Ovarian Cancer","The Immune Landscape of Epithelial Ovarian Cancer: a Prospective Observational Study","IOSI-GYNE-001","Inclusion criteria cohort A-D:\n\n* Suspicious diagnosis of epithelial ovarian cancer (subsequent histologically confirmation required)\n* Plan to undergo a surgical procedure for the management of epithelial ovarian cancer or recurrent ovarian cancer previously treated with conventional treatment and involved in the trial as group A-D\n* ≥18 years old\n* ECOG Performance Status ≤ 2\n* Written informed consent\n\nInclusion criteria cohort E:\n\n* Indication for adnexectomy for a benign gynecological condition\n* ≥18 years old\n* ECOG Performance Status ≤ 2\n* Written informed consent\n\nExclusion criteria cohort A-E:\n\n* Other active concomitant neoplasms that might confound the results of the planned analysis.\n* Ongoing active autoimmune disease requiring treatment or condition of immune deficiency\n* Ongoing chronic treatment with steroids or other immune suppressive agents at the time of study entry",true,"FEMALE",{"count":52,"type":21},"This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC).\n\nPatients with newly diagnosed epithelial OC will be enrolled in 4 different cohorts: A) Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery; B) Newly diagnosed high grade serous or endometroid OC undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery; C) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery; D) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. A cohort of women undergoing adnexectomy for benign pathology will be enrolled (cohort E) for comparative analysis.\n\nEnrolled patients will be asked to provide the following biological samples at specified time points: archival and fresh tumor tissue, peripheral blood samples, rectal and vaginal swabs, ascites (when present).\n\nThe main aim of the study is to characterize the immune landscape of epithelial OC in tumor tissue and peripheral blood and correlate the presence of myeloid-derived suppressive cells (MDSCs) and other immune infiltrates and of the systemic immune response with progression free interval (PFI) in epithelial OC.",[87],"Epithelial Ovarian Cancer",{"date":89,"type":35},"2025-11-18",{"date":91,"type":35},"2022-12-20",{"date":93,"type":21},"2028-12",{"name":41,"class":42},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":53,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":73},"100504580","lifestyle-intervention-in-patients-with-metastatic-prostate-cancer-100504580","NCT05850182","Lifestyle Intervention in Patients With Metastatic Prostate Cancer","A Pilot Study to Investigate the Effects of Lifestyle Intervention on Physical Activity and Diet in Patients With Metastatic Prostate Cancer Receiving Novel Hormonal Agents: the ACTIDIET-PRO Study","ACTIDIET-PRO","Inclusion Criteria:\n\n* Written informed consent according to ICH\u002FGCP regulations before registration.\n* Age ≥ 18 years\n* Histology of adenocarcinoma of the prostate\n* Patients with PCa receiving ADT alone or ADT+NHT (abiraterone, enzalutamide, apalutamide or darolutamide)\n* Rising PSA (two consecutively rising PSA levels \\> 25% above nadir at least three weeks apart), with no evidence of clinical or radiographic progression on instrumental evaluation\n* PSA doubling time \\> 8 weeks\n* Continuation of ongoing systemic treatment is deemed feasible by treating physician\n\nExclusion Criteria:\n\n* Ongoing treatment with docetaxel, cabazitaxel, radionuclides or investigational treatments\n* Evidence of clinical progression or progression of disease on imaging\n* Bone metastases excluding the safety of physical exercise\n* Prior confirmed severe osteoporosis or other diseases affecting the bone with history of fractures\n* Clinically significant cardiovascular disease (i.e. myocardial infarction within 6 months before screening; uncontrolled angina within 3 months before screening; congestive heart failure New York Heart Association class 3 or 4; history of clinically significant arrhythmias; uncontrolled hypertension indicated by systolic blood pressure \\> 170 mm Hg or diastolic blood pressure \\> 105 mm Hg at screening)\n* Clinically significant chronic obstructive pulmonary disease\n* Any concurrent disease or comorbid condition that interferes with the ability of the patient to participate in the study","MALE",{"count":105,"type":21},30,[55],"The proposed pilot study aims at determining the feasibility of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with prostate cancer under androgen deprivation therapy.",[109],"Prostate Cancer",{"date":89,"type":35},{"date":112,"type":35},"2023-11-27",{"date":114,"type":21},"2026-12-31",{"name":41,"class":42},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":53,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":73},"100496738","phase-2-metronidazole-as-preoperative-therapy-in-crc--fusometro-001-100496738","NCT05748145","Metronidazole as Preoperative Therapy in CRC \u002F FusoMetro-001","Preoperative Treatment With Metronidazole to Evaluate the Efficacy in Reducing Fusobacterium Nucleatum Tumor Colonization in Patients With Colorectal Cancer (CRC): a Proof-of-concept Trial","Inclusion Criteria:\n\n* Written informed consent according to ICH\u002FGCP regulations before registration.\n* Age ≥ 18 years old\n* Untreated, primary colorectal adenocarcinoma (\\> 15 cm from the anal verge)\n* Colonoscopy with endoscopic biopsy for disease confirmation and correlative studies.\n* Candidates for surgical resection prior to administration of any therapy.\n\nExclusion Criteria:\n\n* Insufficient material on the tissue biopsy to be left in the archives of the Cantonal Institute of Pathology for further evaluations\u002Fanalyses\n* Known prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives\n* Oral or parenteral antibiotic therapy within the six weeks prior to enrolment\n* Emergency surgery (planned within less than 14 days), where no opportunity to administer preoperative oral antibiotics exists\n* Other malignant disease within 5 years prior to study enrollment, except basocellular or squamous skin cancer and carcinoma in situ cervices uteri\n* Any previous anticancer treatment prior resection\n* Women who are pregnant or breast feeding\n* Fertile women or men who do not use safe contraception during the study period\n* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.),\n* Inability to consent and follow the procedures of the study e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment, affect patient compliance or place the patient at high risk from treatment-related complications",{"count":124,"type":21},40,[126],"PHASE2","The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.",[129],"Colorectal Cancer",{"date":89,"type":35},{"date":132,"type":35},"2023-09-11",{"date":114,"type":21},{"name":41,"class":42},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":73},"100404243","evaluation-of-sleep-quality-in-prostate-cancer-patients-undergoing-treatment-with-hormonal-therapeutic-approaches-and-in-patients-with-full-resected-early-breast-cancer-100404243","NCT04543799","Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer","SIESTA: A Pilot Observational Study to Investigate and Evaluate Sleep Quality in Cancer Patients Undergoing Hormonal Therapeutic Approaches: 1) Localized, Locally Advanced or Metastatic Prostate Cancer Receiving Treatment Including Androgen Deprivation Therapy 2) Full-resected Early (Stage I-III) Breast Cancer, Ductal Carcinoma in Situ or Lobular Carcinoma in Situ, Without Evidence of Residual Disease; Proven Postmenopausal Status","SIESTA","Inclusion Criteria for prostate cancer patients:\n\n* Written infor med consent according to International Conference on Harmonisation (ICH)\u002FGood Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures\n* Histologically proven adenocarcinoma of the prostate\n* Eastern Cooperative Oncology Group performance status 0-2\n* Adult male patient \\> 18 years of age, no upper age limit\n* Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or metastatic hormone-sensitive prostate cancer (mHSPC)\n* ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer\n* Scheduled to receive ADT treatment as SOC for \\> 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone\n\nExclusion Criteria for prostate cancer patients:\n\n* Histology with predominant small cell prostate cancer\n* Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare)\n* Have not received systemic treatment for any other cancer within the last 12 months\n* Active secondary malignancy that requires systemic therapy\n* Any clear contraindications present against treatment with ADT\n* Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \\>15 at baseline\n* Body mass index (BMI) \\> 35 at baseline\n* Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline\n* Severe cardiovascular disease or severe cardiovascular event \\\u003C 6 months\n* History of stroke or other neurologic chronic illnesses \\\u003C 6 months\n* Have demonstrated impaired mental status\n* History of brain tumours, presence of brain metastases or previous cranial irradiation\n* Night shift workers\n* Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening\n* Unhealthy sleep hygiene\n* Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline\n* Present diagnosis of depression or psychiatric illness pharmacologically treated\n* Diagnosis of insomnia and chronic intake of hypnotic medication at baseline\n* Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \\> 25 mg\u002Fday)\n* Any diagnosed condition that causes known sleep disturbance\n\nInclusion criteria for breast cancer patients\n\n* Written informed consent according to International Conference on Harmonisation (ICH)\u002FGood Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures\n* Women with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease\n* Eastern Cooperative Oncology Group performance status 0-2\n* Adult female patient ≥ 18 years of age, no upper age limit\n* Proven postmenopausal status (defined by absence of menstruation for at least 6 months and\u002For level of estradiol \\\u003C40 pg\u002Fml, or bilateral oophorectomy or ovarian irradiation for suppression of ovarian function)\n\nExclusion criteria for breast cancer patients\n\n* Non-epithelial BC or BC with mixed epithelial and non-epithelial histology\n* Previous chemotherapy at any time, in treatment with ET at not standard dosage\n* Have received systemic treatment for any other cancer within the last 12 months\n* Active secondary malignancy that requires systemic therapy\n* Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \\>15 at baseline\n* Body mass index (BMI) \\> 35 at baseline\n* Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline\n* Severe cardiovascular disease or severe cardiovascular event \\\u003C 6 months\n* History of stroke or other neurologic chronic illnesses \\\u003C 6 months\n* Have demonstrated impaired mental status\n* History of brain tumours, presence of brain metastases or previous cranial irradiation\n* Night shift workers\n* Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening\n* Unhealthy sleep hygiene\n* Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline\n* Present diagnosis of depression or psychiatric illness pharmacologically treated\n* Diagnosis of insomnia and chronic intake of hypnotic medication at baseline\n* Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \\> 25 mg\u002Fday) or any diagnosed condition that causes known sleep disturbance",{"count":144,"type":21},60,"This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i) localized, locally advanced or metastatic hormone sensitive prostate cancer or ii) with full-resected early (stage I-III) epithelial breast cancer. The measurements will be taken before androgen deprivation therapy (ADT - for prostate cancer patients) or endocrine therapy (for breast cancer patients) is initiated, at 6 months and some measures again at 12 months.The groups, defined by cancer type and whether or not treatment includes ADT \u002F endocrine therapy, will be compared to see if there are differences in the prevalence of the lowered sleep quality in the groups.",[109,147],"Breast Cancer",{"date":89,"type":35},{"date":150,"type":35},"2020-09-24",{"date":114,"type":21},{"name":41,"class":42},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":73},"100401708","tumor-molecular-profiling-in-early-phase-clinical-trials-100401708","NCT04510766","Tumor Molecular Profiling in Early Phase Clinical Trials","Molecular Characterization of Solid Tumors and Lymphomas to Optimize the Drug Development Process and Patients Enrollment in Early Phase Clinical Trials","Inclusion Criteria:\n\n1. Male or female patients age at least 18 years.\n2. Patients with histological diagnosis of advanced solid tumor or lymphoma who are potential candidates for early phase clinical trials.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n4. Live expectancy of at least 6 months.\n5. Availability of FFPE archival tumor tissue from previous surgery or diagnostic biopsy adequate for molecular analysis.\n6. Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure.\n7. Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n1. Presence of any clinical (e.g. concomitant disease, clinically significant symptoms, or non-clinical (psychological or social) conditions that would not make the patient eligible for enrolment in an early phase clinical trial.\n2. Any other active malignancy (other than the one for which the subject is being assessed for trial option) that is progressing or requiring active treatment with the exception of basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.",{"count":124,"type":21},"Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.",[163,164],"Advanced Solid Tumor","Lymphoma",{"date":89,"type":35},{"date":167,"type":35},"2020-10-01",{"date":114,"type":21},{"name":41,"class":42},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":73},"100317156","valid-biomarkers-in-blood-to-predict-the-response-to-therapy-in-prostate-cancer-patients-100317156","NCT03408964","Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients","An Exploratory proof-of Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients, a Single Center Study","Inclusion Criteria:\n\nGeneral inclusion criteria (for entering all groups)\n\n* Age ≥ 18 years\n* Histological diagnosis of prostate adenocarcinoma at different stages of disease (see Section 6.2) for which a treatment is indicated\n* Written Informed Consent\n\nInclusion criterion only for entering Group 0\n\n• Patients with a known diagnosis of CSPC or CRPC\n\nInclusion criterion only for entering Group 1a\n\n• Patients that underwent biopsies for a suspect of PC, but resulted negative for cancer\n\nExclusion Criteria:\n\nGeneral exclusion criteria (for entering all groups)\n\n* Active infection requiring treatment\n* Decrease of general condition\n* Concomitant severe comorbities\n* Difficult socioeconomic conditions making regular follow up unfeasible.\n* Need of concomitant steroids at study entry and during the study\n* Diagnosis of second tumor in the previous 5 years\n\nExclusion criterion only for entering Group 0\n\n• No antibiotic treatments in the previous 2 months before enrollment\n\nExclusion criteria only for entering Group 1\n\n* Previous radical surgery and \u002F or radical radiotherapy\n* Previous hormonal treatments\n\nExclusion criteria only for entering Group 2\n\n* No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics)\n* Previous hormonal treatments for advanced disease\n\nExclusion criterion only for entering Group 3\n\n• No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics analyses)",{"count":178,"type":21},600,"Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.\n\nIn all patients, 12 ml of blood sample will be collected in EDTA tube for analysis of biological biomarkers in different time points.",[109],{"date":89,"type":35},{"date":183,"type":35},"2017-12-15",{"date":185,"type":21},"2028-12-31",{"name":41,"class":42},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":212,"locationsCount":73},"100307294","liquid-biopsy-in-mature-b-cell-tumors-100307294","NCT03280394","Liquid Biopsy in Mature B-cell Tumors","Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management","Inclusion Criteria:\n\n* Male or female adults 18 years or older\n* Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria\n* Willing and able to comply with scheduled study procedures\n* Evidence of a signed informed consent",{"count":195,"type":21},444,"The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.",[198],"Mature B-Cell Neoplasm",[200,201,202,203,204,205],"Liquid biopsy","Classical Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Mutations","2023-10-31",{"date":208,"type":35},"2023-11-01",{"date":210,"type":35},"2017-09-01",{"date":71,"type":21},{"name":41,"class":42},""]